Welcome to our new website!

Logo TauroLock

TauroLock™

Safe solutions for your central-venous catheter

Central-venous catheters (CVC) help patients in various medical contexts – whether it be dialysis, cancer treatment, or parenteral nutrition. But while vascular access devices (short VAD) can save lives, they also come with considerable risks.

 

To prevent catheter-associated infections, we have developed TauroLock™. This lock solution yields several effects with just one product:

antimicrobial to prevent infections

antibiofilm to keep catheters clean

antiocclusive to maintain a good flow rate

For that purpose, we use several substances: taurolidine, heparin, citrate, and urokinase. TauroLock™ solutions can thus be assigned according to the patient’s individual needs.

Why Do You Need the Right Catheter Lock Solution?

If a CVC system does not remain completely sanitary at all times, it may lead to dangerous infections. Furthermore, it is important to avoid the formation of biofilm within CVCs, which creates a three-dimensional matrix for germs. How do we ensure that central-venous catheters do not cause further complications, or even life-threatening complications? Our answer is: TauroLock™. Unlike traditional lock solutions, we use a combination of active components to realise multiple effects at once.

Taurolidine is antimicrobial:

It kills more than 500 germs without generating resistance. This includes MRSA (methicillin-resistentant staphylococcus aureus) and VRE (vancomycin-resistant enterococci).


 

Heparin and citrate
are anticoagulant:

They prevent occlusion and sustain a patient’s flow rate.


 

Urokinase is fibrinolytic:

It serves to break up blood clotting in early stages.

Taurolock-Gmbh-About-Taurolock-Solutions-Detail-Zuschnitt

Used in the right concentration, these substances provide the basis for a lock solution that prevents catheter-related bloodstream infections (CRBSI) and occlusions.

When Do You Need TauroLock™ Solutions?

Our products are suitable for a wide range of patients. Generally speaking, we recommend using TauroLock™ solutions in all central access devices (CAD) such as used in:

Dialysis

Patients who depend on extracorporeal blood cleansing due to permanent kidney failure may use TauroLock™-Hep500, TauroLock™-U25.000, or TauroLock™.

Oncology

Patients who undergo treatments such as chemotherapy to fight cancer may use TauroLock™, TauroLock™-HEP100, or TauroLock™-U25.000.

Parenteral Nutrition

Patients who need to be fed through a central-venous catheter may use TauroLock™, NutriLock™, TauroLock™-HEP100, or TauroLock™-U25.000.

Intensive Care Units

Patients in ICU should use TauroLock™ or TauroLock™-HEP100 according to their medical condition.

In order to meet the challenges that each patient faces, we have created a customised product line. You may thus choose from various lock solutions containing taurolidine and citrate, as well as heparin (in different dosages) or urokinase.

Product Ingredients Recommended Fields of Application
  • taurolidine
  • 4 % citrate
  • dialysis
  • oncology
  • parenteral nutrition
  • ICU
  • taurolidine
  • 4 % citrate
  • 100 IU/ml of heparin
  • oncology
  • parenteral nutrition
  • ICU
  • taurolidine
  • 4 % citrate
  • 500 IU/ml of heparin
  • dialysis
  • taurolidine
  • 4 % citrate
  • 25,000 IU of urokinase
  • dialysis
  • oncology
  • parenteral nutrition
  • taurolidine
  • parenteral nutrition

Each catheter lock solution from our TauroLock™ series functions both efficiently and safely. Throughout testings, taurolidine has proven to be of good biocompatibility and clinical tolerability: Once the substance enters the body through the VAD, it degrades to taurine (amino acid), carbon dioxide, and water.

Want to Learn More about Our Lock Solutions?

On this website, you can find concise information about the usage und benefits of TauroLock™. If you have any specific questions or concerns, we are happy to help any time. Feel free to contact us via:

Studies on the Efficacy of Lock Solutions

Download study by Torres-Viera et al.

“In vitro, the antimicrobial agent taurolidine inhibited virtually all of the bacteria tested, including vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and Stenotrophomonas maltophilia, at concentrations between 250 and 2,000 mg/ml. Taurolidine was not effective in experimental endocarditis. While it appears unlikely that this antimicrobial would be useful for systemic therapy, its bactericidal activity and the resistance rates found (<10-9) are favorable indicators for its possible development for topical use.”

Download study by Hogan et al.

“…The antiseptics ethanol and Taurolock were shown to be most effective at inactivating biofilm; this was evident against all stages of biofilm investigated...“

For personal inquiries, you may also contact us via phone or e-mail.

Our international distributors based in more than 50 countries are happy to offer support ASAP.